Yeteng Xiong, Fei Luo, Yuhan Huang, Bingnan Li, Guanchuan Lin
Mitogen-activated protein kinase kinase 20 (MAP3K20/ZAK) has emerged as a critical biophysical sensor, uniquely poised at the intersection of environmental stress and cellular fate. Its versatile signaling is primarily orchestrated by two structurally distinct splice variants: ZAKα, which drives the ribotoxic stress response (RSR) upon detecting ribosome collisions, and ZAKβ, which mediates homeostatic mechanotransduction. However, emerging evidence indicates that the biological roles of ZAK cannot be strictly categorized as either pathogenic or protective. It exhibits profound functional plasticity and engages non-canonical metabolic networks in a highly context-dependent manner. Consequently, dysregulated ZAK signaling acts as a powerful disease amplifier across diverse human pathologies, including aggressive malignancies, cardiac remodeling, systemic metabolic deterioration, and inherited myopathies. While targeting ZAK presents a compelling therapeutic opportunity, current broad-spectrum kinase inhibitors are heavily confounded by "on-target, off-tissue" toxicities, particularly within the epidermal barrier. In this review, we synthesize the structural mechanisms, downstream cascades, and complex pathobiology of ZAK. Furthermore, we discuss an emerging Frontier in ZAK pharmacology: the conceptual development of structure-guided, isoform-selective allosteric interventions designed to safely decouple pathogenic ZAKα signaling from essential ZAKβ-mediated tissue homeostasis.